AtriCure said has won an investigational device exemption from the FDA for a first-of-its-kind clinical trial involving patients with non-paroxysmal atrial fibrillation, according to MassDevice.  The trial will combine ablation outside the heart and catheter-based ablation inside the heart to treat more sever afib cases.  For more information on the investigational device grant, please visit: